Structure-activity relationships between the Aconitum C20-diterpenoid alkaloid derivatives and the growth suppressive activities of Non-Hodgkin’s lymphoma Raji cells and human hematopoietic stem/progenitor cells Masaharu HazawaKenji TakahashiIkuo Kashiwakura PRECLINICAL STUDIES 26 September 2009 Pages: 1 - 8
Preclinical activity of F14512, designed to target tumors expressing an active polyamine transport system Anna KruczynskiIsabelle VandenbergheNicolas Guilbaud PRECLINICAL STUDIES 24 September 2009 Pages: 9 - 21
Antitumor activity and toxicity of anti-HER2 immunoRNase scFv 4D5-dibarnase in mice bearing human breast cancer xenografts Taras G. BalandinEvelina EdelweissSergey M. Deyev PRECLINICAL STUDIES 30 September 2009 Pages: 22 - 32
PKC-alpha inhibitor MT477 slows tumor growth with minimal toxicity in in vivo model of non-Ras-mutated cancer via induction of apoptosis Piotr JasinskiPawel ZwolakArkadiusz Z. Dudek PRECLINICAL STUDIES 01 October 2009 Pages: 33 - 40
Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice Jimmie ColonMd. Riyaz BashaMaen Abdelrahim PRECLINICAL STUDIES 23 October 2009 Pages: 41 - 51
Efficacy of Caffeic Acid Phenethyl Ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice Shashi K. KuduguntiNikhil M. VadMajid Y. Moridani PRECLINICAL STUDIES 21 October 2009 Pages: 52 - 62
A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cells Rakesh K. SinghThilo S. LangeLaurent Brard PRECLINICAL STUDIES 29 October 2009 Pages: 63 - 72
Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and—resistant human ovarian cancer cells Gaetano MarvertiAlessio LigabueChiara Frassineti PRECLINICAL STUDIES 16 October 2009 Pages: 73 - 86
Mechanisms for the activity of heterocyclic cyclohexanone curcumin derivatives in estrogen receptor negative human breast cancer cell lines Tiffany J. Somers-EdgarSebastien TaurinRhonda J. Rosengren PRECLINICAL STUDIES 09 October 2009 Pages: 87 - 97
Inhibition of MDR1 activity and induction of apoptosis by analogues of nifedipine and diltiazem: an in vitro analysis Maurizio VialeCinzia CordazzoDomenico Spinelli PRECLINICAL STUDIES 30 October 2009 Pages: 98 - 109
Eugenol inhibits cell proliferation via NF-κB suppression in a rat model of gastric carcinogenesis induced by MNNG P. ManikandanG. VinothiniS. Nagini PRECLINICAL STUDIES 23 October 2009 Pages: 110 - 117
A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer William R. SchelmanGlenn LiuRobert Dreicer PHASE I STUDIES 19 September 2009 Pages: 118 - 125
A phase I study of rebeccamycin analog in combination with oxaliplatin in patients with refractory solid tumors Charles J. NockJoanna M. BrellAfshin Dowlati PHASE I STUDIES 23 September 2009 Pages: 126 - 130
Phase I trial of vinflunine and pemetrexed in refractory solid tumors Hanna K. SanoffJanine DaviesE. Claire Dees PHASE I STUDIES 15 October 2009 Pages: 131 - 136
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors Neeltje SteeghsHans GelderblomHenk-Jan Guchelaar PHASE I STUDIES Open access 19 November 2009 Pages: 137 - 143
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: Results of a Phase II, randomized, noncomparative study Donald A. RichardsPaul R. KueflerSteven J. Nicol PHASE II STUDIES 28 August 2009 Pages: 144 - 153
Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial Byeong-Bae ParkWon Seog KimCheolwon Suh PHASE II STUDIES 16 September 2009 Pages: 154 - 160
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma Karl D. LewisWolfram SamlowskiRene Gonzalez PHASE II STUDIES 15 October 2009 Pages: 161 - 166
A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining Rafal WierzbickiDerek J. JonkerEric K. Rowinsky PHASE II STUDIES 15 October 2009 Pages: 167 - 174
Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma Jae-Cheol JoByung Woog KangCheolwon Suh PHASE II STUDIES 13 October 2009 Pages: 175 - 181
Bevacizumab for salvage treatment of metastatic breast cancer: a systemic review and meta-analysis of randomized controlled trials Jae-Bok LeeOk Hee WooJae Hong Seo SHORT REPORT 16 September 2009 Pages: 182 - 188
Role of Neridronate on MCF-7 estrogen dependent breast cancer model of bone metastasis: a preliminary study Vanessa NicolinPaola NarducciRenato Bareggi SHORT REPORT 02 October 2009 Pages: 189 - 191
TNF-blockade in patients with advanced hormone refractory prostate cancer Luis A. Diaz JrWells MessersmithMario Eisenberger SHORT REPORT 21 October 2009 Pages: 192 - 194